NCT03771664 - A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Participants With Comorbid Major Depressive Disorder (MDD) and Insomnia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 4, 2019

Primary Completion Date

December 20, 2019

Study Completion Date

January 17, 2020

Conditions

Major Depressive DisorderInsomnia

Interventions

DRUG

SAGE-217

Administered as capsules.

DRUG

Placebo

Administered as capsules.

Trial Locations (28)

10019

Sage Investigational Site, New York

11235

Sage Investigational Site, Brooklyn

29407

Sage Investigational Site, Charleston

30030

Sage Investigational Site, Decatur

30331

Sage Investigational Site, Atlanta

30342

Sage Investigational Site, Atlanta

33016

Sage Investigational Site, Miami Lakes

33024

Sage Investigational Site, Hollywood

33161

Sage Investigational Site, North Miami

33912

Sage Investigational Site, Fort Myers

39232

Sage Investigational Site, Flowood

45212

Sage Investigational Site, Cincinnati

45417

Sage Investigational Site, Dayton

60634

Sage Investigational Site, Chicago

63141

Sage Investigational Site, St Louis

70629

Sage Investigational Site, Lake Charles

72211

Sage Investigational Site, Little Rock

72758

Sage Investigational Site, Rogers

73103

Sage Investigational Site, Oklahoma City

78754

Sage Investigational Site, Austin

87109

Sage Investigational Site, Albuquerque

89102

Sage Investigational Site, Las Vegas

92056

Sage Investigational Site, Oceanside

92103

Sage Investigational Site, San Diego

92591

Sage Investigational Site, Temecula

92845

Sage Investigational Site, Garden Grove

97301

Sage Investigational Site, Salem

08009

Sage Investigational Site, Berlin